Kesler Norman & Wride LLC Boosts Holdings in Medtronic PLC $MDT

Kesler Norman & Wride LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 323.4% during the 3rd quarter, Holdings Channel reports. The firm owned 56,831 shares of the medical technology company’s stock after buying an additional 43,410 shares during the quarter. Kesler Norman & Wride LLC’s holdings in Medtronic were worth $5,413,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. 1248 Management LLC purchased a new position in Medtronic during the 1st quarter valued at approximately $26,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic in the second quarter valued at $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic during the third quarter valued at $33,000. Tripletail Wealth Management LLC bought a new position in Medtronic during the third quarter valued at $34,000. Finally, GFG Capital LLC bought a new stake in shares of Medtronic in the 2nd quarter worth about $36,000. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $97.54 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The firm’s 50 day simple moving average is $98.31 and its 200-day simple moving average is $94.45. The firm has a market cap of $125.04 billion, a PE ratio of 26.29, a price-to-earnings-growth ratio of 2.60 and a beta of 0.71. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Citigroup raised their target price on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Morgan Stanley raised their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Finally, Wells Fargo & Company boosted their target price on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and an average target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).